These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
227 related articles for article (PubMed ID: 28948755)
21. Outcome of hepatitis C-related liver transplantation in direct-acting antiviral era. Choudhary NS; Saraf N; Saigal S; Rastogi A; Bhangui P; Thiagrajan S; Soin AS Indian J Gastroenterol; 2020 Dec; 39(6):539-543. PubMed ID: 33230754 [TBL] [Abstract][Full Text] [Related]
22. Predictors of hepatitis C virus recurrence after living donor liver transplantation: Mansoura experience. Abdel-Wahab M; Abdel-Khalek EE; El-Gilany AH; Yassen AM; Al-Shobari M; Shiha U; Ali M; Sadani M; Salah T; Sultan AM; Elghawalby AN; Elmorshedi M; Al-Refaey AK; Abdalla U Arab J Gastroenterol; 2017 Sep; 18(3):151-155. PubMed ID: 28958486 [TBL] [Abstract][Full Text] [Related]
23. The future of liver transplantation for viral hepatitis. Durand F; Francoz C Liver Int; 2017 Jan; 37 Suppl 1():130-135. PubMed ID: 28052618 [TBL] [Abstract][Full Text] [Related]
24. Optimal timing for hepatitis C therapy in US patients eligible for liver transplantation: a cost-effectiveness analysis. Njei B; McCarty TR; Fortune BE; Lim JK Aliment Pharmacol Ther; 2016 Nov; 44(10):1090-1101. PubMed ID: 27640785 [TBL] [Abstract][Full Text] [Related]
25. Perspectives on treating hepatitis C infection in the liver transplantation setting. Chen T; Terrault NA Curr Opin Organ Transplant; 2016 Apr; 21(2):111-9. PubMed ID: 26927201 [TBL] [Abstract][Full Text] [Related]
26. Pre- and Post-Transplant Treatment of Viral Hepatitis C. Mutimer D Dig Dis; 2017; 35(4):347-350. PubMed ID: 28468002 [TBL] [Abstract][Full Text] [Related]
27. Use of direct-acting antiviral agents in hepatitis C virus-infected liver transplant candidates. Gadiparthi C; Cholankeril G; Perumpail BJ; Yoo ER; Satapathy SK; Nair S; Ahmed A World J Gastroenterol; 2018 Jan; 24(3):315-322. PubMed ID: 29391754 [TBL] [Abstract][Full Text] [Related]
28. Treatment of patients waitlisted for liver transplant with all-oral direct-acting antivirals is a cost-effective treatment strategy in the United States. Ahmed A; Gonzalez SA; Cholankeril G; Perumpail RB; McGinnis J; Saab S; Beckerman R; Younossi ZM Hepatology; 2017 Jul; 66(1):46-56. PubMed ID: 28257591 [TBL] [Abstract][Full Text] [Related]
29. Liver transplantation for hepatitis C virus in the era of direct-acting antiviral agents. Coilly A; Bruno R Curr Opin HIV AIDS; 2015 Sep; 10(5):361-8. PubMed ID: 26185921 [TBL] [Abstract][Full Text] [Related]
30. Directly acting antivirals (DAAs) for the treatment of chronic hepatitis C virus infection in liver transplant patients: "a flood of opportunity". Gane EJ; Agarwal K Am J Transplant; 2014 May; 14(5):994-1002. PubMed ID: 24730431 [TBL] [Abstract][Full Text] [Related]
31. Liver transplantation in the setting of chronic HCV. Terrault N Best Pract Res Clin Gastroenterol; 2012 Aug; 26(4):531-48. PubMed ID: 23199510 [TBL] [Abstract][Full Text] [Related]
32. A pleasant dilemma to have: to treat the HCV patient on the waiting list or to treat post-liver transplantation? Barsa JE; Branch AD; Schiano TD Clin Transplant; 2015 Oct; 29(10):859-65. PubMed ID: 26329668 [TBL] [Abstract][Full Text] [Related]
33. News and challenges in the treatment of hepatitis C in liver transplantation. Coilly A; Roche B; Duclos-Vallée JC; Samuel D Liver Int; 2016 Jan; 36 Suppl 1():34-42. PubMed ID: 26725895 [TBL] [Abstract][Full Text] [Related]
34. IFN-free therapy for HIV/HCV-coinfected patients within the liver transplant setting. Londoño MC; Manzardo C; Rimola A; Ruiz P; Costa J; Forner A; Ambrosioni J; Agüero F; Laguno M; Lligoña A; Moreno A; Miró JM J Antimicrob Chemother; 2016 Nov; 71(11):3195-3201. PubMed ID: 27402009 [TBL] [Abstract][Full Text] [Related]
35. Utilization of hepatitis C viremic donors for liver transplant recipients without hepatitis C. A veterans transplant center report. Said A; Weiss M; Varhelyi A; Farago R; Ballweg C; Rice J; Agarwal P; Fernandez L; Foley D Transpl Infect Dis; 2021 Apr; 23(2):e13466. PubMed ID: 32931616 [TBL] [Abstract][Full Text] [Related]
36. A systematic review of direct acting antiviral therapies in hepatitis C virus-negative liver transplant recipients of hepatitis C-viremic donors. Snyder HS; Wiegel JJ; Khalil K; Summers BB; Tan T; Jonchhe S; Kaiser TE Pharmacotherapy; 2022 Dec; 42(12):905-920. PubMed ID: 36373198 [TBL] [Abstract][Full Text] [Related]
37. Transplanting hepatitis C virus-positive livers into hepatitis C virus-negative patients with preemptive antiviral treatment: A modeling study. Chhatwal J; Samur S; Bethea ED; Ayer T; Kanwal F; Hur C; Roberts MS; Terrault N; Chung RT Hepatology; 2018 Jun; 67(6):2085-2095. PubMed ID: 29222916 [TBL] [Abstract][Full Text] [Related]
38. Retransplantation outcomes for hepatitis C in the United States before and after direct-acting antiviral introduction. Ivanics T; Rizzari M; Moonka D; Al-Kurd A; Delvecchio K; Kitajima T; Elsabbagh AM; Collins K; Yoshida A; Abouljoud M; Nagai S Am J Transplant; 2021 Mar; 21(3):1100-1112. PubMed ID: 32794649 [TBL] [Abstract][Full Text] [Related]
39. High sustained virological response to pegylated interferon and ribavirin for recurrent genotype 3 hepatitis C infection post-liver transplantation. Faisal N; Mumtaz K; Marquez M; Renner EL; Lilly LB Hepatol Int; 2015 Jan; 9(1):76-83. PubMed ID: 25788382 [TBL] [Abstract][Full Text] [Related]
40. Liver transplantation for hepatitis B virus: Decreasing indication and changing trends. Al-Hamoudi W; Elsiesy H; Bendahmash A; Al-Masri N; Ali S; Allam N; Al Sofayan M; Al Bahili H; Al Sebayel M; Broering D; Saab S; Abaalkhail F World J Gastroenterol; 2015 Jul; 21(26):8140-7. PubMed ID: 26185387 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]